Table 2. The number of NGS-positive cases and relative incidence in order of sites of tumor origin and type of used panel.

	Panel 1	Panel 2	Global positivity incidence for tumor type
Intestine	7/14 (50%)	9/14 (64%)	9/14 (64%)
Lung	7/17 (41%)	7/17 (41%)	11/17 (65%)
Others	2/8 (25%)	4/8 (50%)	5/8 (62%)
Global positivity incidence for panel type	16/39 (41%)	20/39 (51%)

Abbreviations: NGS, next-generation sequencing.

Note: The maximum incidence values per pathology category are shown in bold.